“We are extremely excited to be nearing completion of what we believe to be the world’s first SVM-based image analysis mobile phone App for assessing the risk for melanoma and other skin cancers from pictures taken of skin lesions such as moles in the privacy of one's home,” said Stephen D. Barnhill, M.D., Chairman and CEO of Health Discovery Corporation. “When released, our melanoma/skin cancer risk assessment App could become a commonly used tool for identifying skin cancers such as melanoma in an affordable, objective and fast manner that can be used world-wide wherever mobile phones with cameras are available. With most people having moles and many having cell phones with cameras, the world-wide market for HDC's new melanoma/skin cancer App is huge." Dr. Barnhill continued, “Our new melanoma/skin cancer cell phone App could be used to regularly check and help identify potentially life-threatening cancerous lesions at an early stage before they become advanced metastatic cancers and we will encourage our customers to seek prompt professional, medical evaluation through a global physician and clinical laboratory referral network established by the Company."To help our customers get state-of-the-art expert medical care for their melanoma and other skin cancers, Health Discovery Corporation intends to create a worldwide network of partners that includes physicians who perform skin biopsies and clinical pathology laboratories that analyze skin biopsies. To assure the privacy of their results, Customers using HDC's melanoma/skin cancer risk assessment App may submit their image anonymously, if they so choose. Even if the customers wish to submit their images anonymously, by using the mobile phone’s GPS location feature, Health Discovery Corporation will be able to provide the melanoma/skin cancer risk evaluation results and a nearby physician and/or clinical pathology laboratory referral to the customer through our network of paid subscribers electing to become part of HDC's referral base.
Health Discovery Corporation is creating a three-tier revenue model for this service that includes a melanoma/skin cancer risk assessment fee charged to customers for each image submitted as well as an opt-in subscription fee charged to physicians and clinical laboratories that choose to participate as members of our worldwide referral network.Health Discovery Corporation owns all of the intellectual property and commercialization rights to this mobile phone melanoma/skin cancer App. Those customers without a mobile phone, may upload their digital camera pictures to HDC's melanoma/skin cancer App website to receive the same service. It is reported that the incidence of melanoma has more than tripled in the Caucasian population during the last 20 years. It is estimated that approximately 68,720 Americans (39,080 men and 29,640 women) developed invasive skin melanoma in 2009, with an estimated additional 53,120 or more cases of melanoma that have not yet metastasized. According to a 2006 World Health Organization study, there were approximately 211,921 cases of malignant melanoma and 65,161 melanoma deaths worldwide in 2000, while the burden of the melanoma disease affected hundreds of thousands of people. About Health Discovery Corporation Health Discovery Corporation is a molecular diagnostics company that uses advanced mathematical techniques to analyze large amounts of data to uncover patterns that might otherwise be undetectable. It operates primarily in the emerging field of personalized medicine where such tools are critical to scientific discovery. Its primary business consists of licensing its intellectual property and developing its own product line of biomarker-based diagnostic tests that include human genes and genetic variations, as well as gene, protein, and metabolic expression differences and image analysis in digital pathology and radiology. For more information, see www.healthdiscoverycorp.com. Forward-Looking Statements This document contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, the accuracy of which is necessarily subject to risks and uncertainties, including, without limitation, statements regarding future performance, opportunities and investments, and anticipated results in general. From time to time the Company may make other forward-looking statements relation to other matters, including without limitation, commercialization plans and strategic partnerships. Actual results may differ materially due to a variety of factors, including, among other things, the acceptance of our approach to applying mathematics computer science and physics into the disciplines of biology, organic chemistry and medicine and our products and technologies associated with those approaches, the ability to develop and commercialize new drugs, therapies or other products based on our approaches, and other factors set forth from time to time in the Company’s Securities and Exchange Commission filings.
All forward-looking statements and cautionary statements included in this document are made as of the date hereof based on information available to the Company as of the date hereof, and the Company assumes no obligation to update any forward-looking statement or cautionary statement.